Autoantibody signature in human ductal pancreatic adenocarcinoma

Barbara Tomaino, Paola Cappello, Michela Capello, Claudia Fredolini, Antonio Ponzetto, Anna Novarino, Libero Ciuffreda, Oscar Bertetto, Claudio De Angelis, Enzo Gaia, Paola Salacone, Michele Milella, Paola Nisticò, Massimo Alessio, Roberto Chiarle, Maria G. Giuffrida, Mirella Giovarelli, Francesco Novelli

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by rapid progression, invasiveness, and resistance to treatment. It is the fourth leading cause of cancer death with a 2% 5-year survival rate. Biomarkers for its early detection are lacking. This study was designed to use a proteomics-based approach as a means of identifying antigens that elicit a humoral response in PDAC patients. Antibodies against PDAC-associated antigens are useful for early cancer diagnosis and therapy. Proteins from PDAC cell lines were separated by 2-DE, and the serum IgG reactivity of 70 PDAC patients, 40 healthy subjects (HS), 30 non-PDAC tumor patients, and 15 chronic pancreatitis (CP) patients was tested by Western blot analysis. Spots specifically recognized by PDAC sera and revealed by mass spectrometry corresponded to metabolic enzymes or cytoskeletal proteins. Most were up-regulated in PDAC tissues. Thus, it seems that metabolic enzymes and cytoskeletal proteins are specific targets of the humoral response during PDAC. The results of further studies of these serological-defined antigens could be of diagnostic and therapeutic significance in PDAC.

Original languageEnglish
Pages (from-to)4025-4031
Number of pages7
JournalJournal of Proteome Research
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Autoantibodies
Adenocarcinoma
Cytoskeletal Proteins
Antigens
Biomarkers
Enzymes
Mass spectrometry
Tumors
Immunoglobulin G
Cells
Tissue
Antibodies
Neoplasms
Proteins
Chronic Pancreatitis
Secondary Prevention
Serum
Proteomics
Cause of Death
Mass Spectrometry

Keywords

  • Autoantibody
  • Mass spectrometry
  • Pancreatic ductal adenocarcinoma
  • Tumor associated antigen
  • Two-dimensional electrophoresis

ASJC Scopus subject areas

  • Genetics
  • Biotechnology
  • Biochemistry

Cite this

Tomaino, B., Cappello, P., Capello, M., Fredolini, C., Ponzetto, A., Novarino, A., ... Novelli, F. (2007). Autoantibody signature in human ductal pancreatic adenocarcinoma. Journal of Proteome Research, 6(10), 4025-4031. https://doi.org/10.1021/pr070281a

Autoantibody signature in human ductal pancreatic adenocarcinoma. / Tomaino, Barbara; Cappello, Paola; Capello, Michela; Fredolini, Claudia; Ponzetto, Antonio; Novarino, Anna; Ciuffreda, Libero; Bertetto, Oscar; De Angelis, Claudio; Gaia, Enzo; Salacone, Paola; Milella, Michele; Nisticò, Paola; Alessio, Massimo; Chiarle, Roberto; Giuffrida, Maria G.; Giovarelli, Mirella; Novelli, Francesco.

In: Journal of Proteome Research, Vol. 6, No. 10, 10.2007, p. 4025-4031.

Research output: Contribution to journalArticle

Tomaino, B, Cappello, P, Capello, M, Fredolini, C, Ponzetto, A, Novarino, A, Ciuffreda, L, Bertetto, O, De Angelis, C, Gaia, E, Salacone, P, Milella, M, Nisticò, P, Alessio, M, Chiarle, R, Giuffrida, MG, Giovarelli, M & Novelli, F 2007, 'Autoantibody signature in human ductal pancreatic adenocarcinoma', Journal of Proteome Research, vol. 6, no. 10, pp. 4025-4031. https://doi.org/10.1021/pr070281a
Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. Journal of Proteome Research. 2007 Oct;6(10):4025-4031. https://doi.org/10.1021/pr070281a
Tomaino, Barbara ; Cappello, Paola ; Capello, Michela ; Fredolini, Claudia ; Ponzetto, Antonio ; Novarino, Anna ; Ciuffreda, Libero ; Bertetto, Oscar ; De Angelis, Claudio ; Gaia, Enzo ; Salacone, Paola ; Milella, Michele ; Nisticò, Paola ; Alessio, Massimo ; Chiarle, Roberto ; Giuffrida, Maria G. ; Giovarelli, Mirella ; Novelli, Francesco. / Autoantibody signature in human ductal pancreatic adenocarcinoma. In: Journal of Proteome Research. 2007 ; Vol. 6, No. 10. pp. 4025-4031.
@article{029eb322e926453491efca361145f484,
title = "Autoantibody signature in human ductal pancreatic adenocarcinoma",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by rapid progression, invasiveness, and resistance to treatment. It is the fourth leading cause of cancer death with a 2{\%} 5-year survival rate. Biomarkers for its early detection are lacking. This study was designed to use a proteomics-based approach as a means of identifying antigens that elicit a humoral response in PDAC patients. Antibodies against PDAC-associated antigens are useful for early cancer diagnosis and therapy. Proteins from PDAC cell lines were separated by 2-DE, and the serum IgG reactivity of 70 PDAC patients, 40 healthy subjects (HS), 30 non-PDAC tumor patients, and 15 chronic pancreatitis (CP) patients was tested by Western blot analysis. Spots specifically recognized by PDAC sera and revealed by mass spectrometry corresponded to metabolic enzymes or cytoskeletal proteins. Most were up-regulated in PDAC tissues. Thus, it seems that metabolic enzymes and cytoskeletal proteins are specific targets of the humoral response during PDAC. The results of further studies of these serological-defined antigens could be of diagnostic and therapeutic significance in PDAC.",
keywords = "Autoantibody, Mass spectrometry, Pancreatic ductal adenocarcinoma, Tumor associated antigen, Two-dimensional electrophoresis",
author = "Barbara Tomaino and Paola Cappello and Michela Capello and Claudia Fredolini and Antonio Ponzetto and Anna Novarino and Libero Ciuffreda and Oscar Bertetto and {De Angelis}, Claudio and Enzo Gaia and Paola Salacone and Michele Milella and Paola Nistic{\`o} and Massimo Alessio and Roberto Chiarle and Giuffrida, {Maria G.} and Mirella Giovarelli and Francesco Novelli",
year = "2007",
month = "10",
doi = "10.1021/pr070281a",
language = "English",
volume = "6",
pages = "4025--4031",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Autoantibody signature in human ductal pancreatic adenocarcinoma

AU - Tomaino, Barbara

AU - Cappello, Paola

AU - Capello, Michela

AU - Fredolini, Claudia

AU - Ponzetto, Antonio

AU - Novarino, Anna

AU - Ciuffreda, Libero

AU - Bertetto, Oscar

AU - De Angelis, Claudio

AU - Gaia, Enzo

AU - Salacone, Paola

AU - Milella, Michele

AU - Nisticò, Paola

AU - Alessio, Massimo

AU - Chiarle, Roberto

AU - Giuffrida, Maria G.

AU - Giovarelli, Mirella

AU - Novelli, Francesco

PY - 2007/10

Y1 - 2007/10

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by rapid progression, invasiveness, and resistance to treatment. It is the fourth leading cause of cancer death with a 2% 5-year survival rate. Biomarkers for its early detection are lacking. This study was designed to use a proteomics-based approach as a means of identifying antigens that elicit a humoral response in PDAC patients. Antibodies against PDAC-associated antigens are useful for early cancer diagnosis and therapy. Proteins from PDAC cell lines were separated by 2-DE, and the serum IgG reactivity of 70 PDAC patients, 40 healthy subjects (HS), 30 non-PDAC tumor patients, and 15 chronic pancreatitis (CP) patients was tested by Western blot analysis. Spots specifically recognized by PDAC sera and revealed by mass spectrometry corresponded to metabolic enzymes or cytoskeletal proteins. Most were up-regulated in PDAC tissues. Thus, it seems that metabolic enzymes and cytoskeletal proteins are specific targets of the humoral response during PDAC. The results of further studies of these serological-defined antigens could be of diagnostic and therapeutic significance in PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by rapid progression, invasiveness, and resistance to treatment. It is the fourth leading cause of cancer death with a 2% 5-year survival rate. Biomarkers for its early detection are lacking. This study was designed to use a proteomics-based approach as a means of identifying antigens that elicit a humoral response in PDAC patients. Antibodies against PDAC-associated antigens are useful for early cancer diagnosis and therapy. Proteins from PDAC cell lines were separated by 2-DE, and the serum IgG reactivity of 70 PDAC patients, 40 healthy subjects (HS), 30 non-PDAC tumor patients, and 15 chronic pancreatitis (CP) patients was tested by Western blot analysis. Spots specifically recognized by PDAC sera and revealed by mass spectrometry corresponded to metabolic enzymes or cytoskeletal proteins. Most were up-regulated in PDAC tissues. Thus, it seems that metabolic enzymes and cytoskeletal proteins are specific targets of the humoral response during PDAC. The results of further studies of these serological-defined antigens could be of diagnostic and therapeutic significance in PDAC.

KW - Autoantibody

KW - Mass spectrometry

KW - Pancreatic ductal adenocarcinoma

KW - Tumor associated antigen

KW - Two-dimensional electrophoresis

UR - http://www.scopus.com/inward/record.url?scp=35649019358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649019358&partnerID=8YFLogxK

U2 - 10.1021/pr070281a

DO - 10.1021/pr070281a

M3 - Article

C2 - 17824682

AN - SCOPUS:35649019358

VL - 6

SP - 4025

EP - 4031

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 10

ER -